CCL2 (Monocyte Chemoattractant Protein-1) in cancer bone metastases

  title={CCL2 (Monocyte Chemoattractant Protein-1) in cancer bone metastases},
  author={Matthew J. Craig and Robert D. Loberg},
  journal={Cancer and Metastasis Reviews},
The paradigm of cancer development and metastasis is a comprehensive, complex series of events that ultimately reflects a coordinated interaction between the tumor cell and the microenvironment within which the tumor cell resides. Despite the realization that this relationship has changed the current paradigm of cancer research, the struggle continues to more completely understand the pathogenesis of the disease and the ability to appropriately identify and design novel targets for therapy. A… 
CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis.
CCL2/CCR2 signaling in cancer pathogenesis
The therapeutic potential of CCL2/CCR2 axis in cancer treatment is discussed based on results from the authors' group and other investigators, with a major focus on prostate cancer.
Chemokines in tumor angiogenesis and metastasis
The diverse functions of chemokines establish them as key mediators between the tumor cells and their microenvironment and play critical role in tumor progression and metastasis.
Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth.
The multiple roles of CCL2 in the tumor microenvironment make it an attractive therapeutic target in metastatic prostate cancer as well as in other cancers.
Chemokines and Metastasis
This chapter will review recent advances in chemokine research with special emphasis on their role in host–tumor interaction during tumor progression, angiogenesis, and metastasis.
Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models
Overall, the data indicate that bindarit is a good candidate for new therapies against prostate and breast tumorigenesis, with an action through impairment of inflammatory cell responses during formation of the tumor–stroma niche microenvironment.
The Versatile World of Inflammatory Chemokines in Cancer
It is proposed that inflammatory chemokines and their receptors are attractive therapeutic targets in malignancy, and the expected difficulties in translating such approaches in the clinic are discussed.
The role of macrophages in bone metastasis


Chemokines in human colorectal carcinoma.
Therapeutic studies in colorectal carcinomas should focus more on the neutralization of CKs than on their application, as all CK analyzed were expressed at a significantly higher level in malignant tissue.
Significant correlation of monocyte chemoattractant protein‐1 expression with neovascularization and progression of breast carcinoma
Tumor‐associated macrophages are known to play a crucial role in tumor progression and MCP‐1 is one of the major chemokines capable of inducing chemotactic migration of monocytes.
Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer.
  • T. Ueno, M. Toi, K. Matsushima
  • Biology
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2000
Interaction between the immune network system and angiogenesis is important for progression of human breast cancer, and that MCP-1 may play an important role in the regulation of angiogenic and the immune system is indicated.
A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell–microenvironment interactions
These therapies target cancer cell growth early and interrupt the vicious cycle that is created by the tumor cells interacting with bone components by inhibiting osteoclasts, osteoblasts, stromal cells, and endothelial cells.
CCL2 is a potent regulator of prostate cancer cell migration and proliferation.
It is shown that human bone marrow endothelial cells secrete significantly higher levels of CCL2 compared to human aortic endothelium cells and human dermal microvascular endothelial Cells, and that an elevated secretion of Ccl2 recruits prostate cancer epithelial cells to the bone microenvironment and regulates their proliferation rate.
Monocyte chemotactic protein‐1 (MCP‐1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion
The role of MCP‐1 on prostate cancer (CaP) cell proliferation and invasion is evaluated by evaluating its role in the recruitment and activation of monocytes during inflammation.
The expression of monocyte chemoattractant protein-1 and other chemokines by osteoblasts.
It is established that MCP-1 is induced during osseous inflammation and in developmentally regulated bone remodelling, and is associated with enhanced monocyte recruitment when applied to osseus lesions.
The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity.
Results suggest that CCL2 could be a relevant negative regulator of pancreatic cancer progression and other proinflammatory cytokines such as tumor necrosis factor alpha and IFN-gamma appeared able to induce apoptosis and to reduce the proliferative rate of pancreating cancer.
Tumor‐driven matrix invasion by infiltrating lymphocytes: involvement of the α1 integrin I‐domain
Here we show that tumor cells (TC) from renal cancers regulate the migratory properties of autologous tumor‐infiltrating lymphocytes (TIL), enhancing their ability to invade the extracellular matrix.